Health Care/Hospital
CIVCO Radiotherapy and Qfix Showcase as One Company at ESTRO 2023
CORALVILLE, Iowa, May 8, 2023 /PRNewswire/ -- CIVCO Radiotherapy and Qfix, now together as one company, will exhibit their innovative and patented solutions during the annual ESTRO Congress inVienna, Austria, 12-16 May 2023. The company encourages attendees to visit booth #200 to experience many ...
2023-05-08 22:00
2281
EmeTerm Anti Fatigue & Car Sickness Wristband Wins the IF and IDA Design Awards
VANCOUVER, BC, May 8, 2023 /PRNewswire/ -- Improving the driving experience of drivers and passengers has been one of the directions of innovation in the automotive industry for many years. To address motion sickness and driving fatigue, automakers are working to develop a variety of technologies...
2023-05-08 21:00
1917
PharmAbcine to participate in "BIO International Convention 2023"
DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in the upcoming BIO International Convention 2023. Details...
2023-05-08 20:00
1844
Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
NEWARK, Del. and NANJING, China, May 8, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentation of discovery and development data for BSI-038, an anti-CD40 agonistic antibody at the PEGS Boston conference to be held from May ...
2023-05-08 19:30
1550
Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China
HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in Greater China (Mainland China, Taiwan, Hong Kong, and Macao). INBRIJA is indicated in the United ...
2023-05-08 19:30
1505
Thai developer MQDC's 'The Aspen Tree' residential project moves to capture surging demand from over-50s for developments designed around their own generational needs
Offers special assistance to people not currently resident in Thailand as well as 1-year and 5-year trial residential packagesand almost US$ 70,000 in introductory benefits "Under The Aspen Tree's lifetime care concept, through a single, one-time home and services buying payment, residents are p...
2023-05-08 19:22
2557
Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases
* HMBD-011 is a potentially first-in-class anti-VH4-34 antibody developed for treatment of VH4-34+ antibody-driven pathogenesis in lupus and cold agglutinin disease * Data presented shows preclinical proof of concept for HMBD-011 clearance of VH4-34+ antibodies and effective inhibition of col...
2023-05-08 18:30
1980
Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed that ...
2023-05-08 16:50
2461
MEDICAL IP Is Creating Medical Digital Twins in Virtual Spaces, Powered by NVIDIA Omniverse
* MEDIP PRO, a real-time digital twin implementation solution based on medical imaging, is now connected to NVIDIA Omniverse * Maximize medical data scalability by sharing and simulating medical-imaging-based digital twins without time and space limitations SEOUL, South Korea and SANTA CLARA,...
2023-05-08 16:00
1752
Transcenta to Present Two Clinical Trial Progress at ASCO 2023
SUZHOU, China, May 8, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that two posters for c...
2023-05-08 14:55
2061
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck
CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) diseases, announced today the signing of an exclusive, worldwide...
2023-05-08 14:00
1551
Bolivian and Taiwanese Experts Discuss the Latest Med-Tech Developments to Position Bolivia as a Leading hub in Robotic Neurosurgery
HSINCHU, May 8, 2023 /PRNewswire/ -- Medical experts from Bolivia and Taiwan recently joined forces to explore the latest technological advancements in surgical navigation robots and their potential to positionBolivia as a leader in robotic neurosurgery. During the largest robotic surgery online ...
2023-05-08 13:29
2260
Genomenon Recognized by Frost & Sullivan for Genomic Intelligence Solutions and Software for Pharma and Clinical Diagnostics Companies
Genomenon's unique blend of AI technology and expert scientific review delivers deep genomic insights into genetic drivers of rare diseases and cancer. SAN ANTONIO, May 8, 2023 /PRNewswire/ -- Frost & Sullivan today announced that it has awardedGenomenon with the 2023 Global Technology Innovation...
2023-05-08 12:01
1991
EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
TAIPEI, May 8, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A inEurope. Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show th...
2023-05-08 10:00
2036
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-08 08:00
3179
Duoning Biotech Celebrates Ground Breaking for Its Global Headquarters
SHANGHAI, May 8, 2023 /PRNewswire/ -- On May 6th, the "2023 Commencement Ceremony for Major Industrial Projects in Fengxian and for Duoning's Global Headquarters and Industrialization Base" was held grandly in the Biotechnology Park. Leaders of the Fengxian district, representatives of the Orient...
2023-05-08 08:00
2190
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-08 08:00
3859
World Lupus Federation Urges Global Community to Raise Lupus Awareness on May 10 for World Lupus Day 2023
Lupus awareness tools, facts and resources available at WorldLupusDay.org/tool-kit WASHINGTON, May 8, 2023 /PRNewswire/ -- World Lupus Day was established to take place onMay 10 by the World Lupus Federation (WLF) to unite lupus groups around the world during Lupus Awareness Month and call atten...
2023-05-08 08:00
2300
BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701
HANGZHOU, China, May 7, 2023 /PRNewswire/ -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("BlissBio") a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a clinical trial collaboration agreement with option for strategic coll...
2023-05-08 07:00
2098
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Pha...
2023-05-08 05:00
5289
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 323 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
9824
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
8164
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
7735
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
7343
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
7008
